Introduction {#s1}
============

Cancers arise through an evolutionary process that feeds from stochastic genetic alterations and selection ([@bib68]). The identities of the alterations that get selected for are rapidly coming to light through large-scale resequencing efforts. For example, several independent studies have characterized the mutational complement of breast cancer, one of the most common human malignancies ([@bib58]; [@bib64]; [@bib21]; [@bib5]; [@bib15]; [@bib59]; [@bib65]). Besides confirming previously known cancer genes, such as *TP53* and *PIK3CA*, most studies also report a long tail of rarely mutated genes. While many of these mutations are likely to be passenger events, some of them are potential mediators of tumor phenotypes. How to identify such low-frequency driver mutations remains a challenge.

In addition to mutations that directly promote tumorigenesis through specific alterations in cell signaling and repair pathways, many aberrations found in cancers do not affect cell signaling pathways directly, but rather, they support the stabilization of altered transcriptomic profiles that facilitate the emergence of pro-tumorigenic and metastatic traits. Mutations in epigenetic regulators fall into this category ([@bib61]). The phenotypic output of such alterations would depend on the activity of already existing signaling processes. Indeed, examples of epigenetic alterations that result in a phenotypic trait in the presence of a specific transcriptional program have been described ([@bib67]). Analogously, aberrations in the multi-step mRNA processing and turnover cascade ([@bib47]) could also lock in aberrant transcriptomic states.

Precise regulation of RNA metabolism is fundamental in the generation of biological complexity in both normal and disease states ([@bib60]; [@bib38]). The concerted action of multiple RNA binding proteins (RBPs) regulate the spatial, temporal and functional dynamics of the transcriptome via alternative splicing, alternative polyadenylation and transcript stability ([@bib47]). While malignancy-associated dysregulation of RNA metabolism via aberrant microRNA expression is relatively well established ([@bib20]; [@bib53]), a growing body of evidence indicates a prominent role also for RBPs in both the development and progression of cancer. For example, upregulation of the splicing regulator SRSF1 is associated with multiple tumor types ([@bib32]), and is necessary for the oncogenic activity of MYC in lung cancer ([@bib19]). Conversely, RBM5 has been shown to be tumor suppressive in several cancer models ([@bib49]; [@bib48]; [@bib50]).

We hypothesized that combining cancer genome resequencing data with gene expression information from both clinical data sets and experimental model systems of metastasis would allow the identification of rarely mutated cancer genes with potential functional significance. This approach identified *RNA binding motif protein 47 (RBM47)* as a suppressor of breast cancer progression. By analyzing the transcriptome-wide RBM47 binding patterns we demonstrate that RBM47, a previously uncharacterized RNA-binding protein, modulates mRNA splicing and stability. Loss of RBM47 function thus provides a specific example of the power of global RNA modulatory events in the selection of pro-metastatic phenotypic traits.

Results {#s2}
=======

RBM47 inactivation associated with breast cancer progression {#s2-1}
------------------------------------------------------------

We combined gene expression data from triple negative metastatic breast cancer models ([@bib46]; [@bib7]) and a cohort of 368 untreated clinical breast cancer cases ([@bib46]; [@bib70]) with mutational data from a brain metastasis that originated from a basal breast cancer ([@bib21]; [Figure 1A](#fig1){ref-type="fig"}). Specifically, we looked for genes that had reduced mRNA expression in functionally metastatic cancer cells, evidence for low mRNA expression associated with poor patient outcome in clinical samples, and an enriched mutation in the brain metastasis sequenced by [@bib21]. *RBM47*, a gene encoding a previously uncharacterized putative RNA-binding protein was the only one that fulfilled all these criteria ([@bib4]; [@bib8]; [@bib54]). We confirmed the lower expression of *RBM47* mRNA in the highly metastatic cells ([Figure 1B](#fig1){ref-type="fig"}). This translated into a comparable difference at the protein level ([Figure 1C](#fig1){ref-type="fig"}). In the clinical data sets, low *RBM47* mRNA expression was significantly associated with relapse to brain and lung ([Figure 1D,E](#fig1){ref-type="fig"}) but not to bone ([Figure 1F](#fig1){ref-type="fig"}). In multivariate analysis combining *RBM47* expression with estrogen, progesterone and HER2 receptor status (ER, PR and HER2), the association with brain metastasis remained statistically significant ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). We further characterized the expression patterns of *RBM47* in the TCGA cohort of 748 breast cancer samples studied by RNA-seq ([@bib9]; [@bib15]). We found that low *RBM47* expression was significantly associated with claudin-low and basal breast cancers ([Figure 1G](#fig1){ref-type="fig"}), two subtypes of poor prognosis ([@bib62]; [@bib41]).10.7554/eLife.02734.003Figure 1.RBM47 expression associated with breast cancer progression.(**A**) A schematic of the analytical approach. Genes identified as mutated in a breast cancer brain metastasis by [@bib21] where compared to metastasis-associated gene expression traits in both clinical data sets and experimental model systems. This identified *RBM47* as a putative breast cancer suppressor gene. (**B**) *RBM47* mRNA expression measured by quantitative real-time RT-PCR in two cell line systems of breast cancer metastasis. In both panels, the data are normalized to the parental cell line (Par). Error bars represent 95% confidence intervals obtained from multiple PCR reactions. LM, lung metastatic derivative; BoM, bone metastatic derivative; BrM, brain metastatic derivative. (**C**) RBM47 protein expression measured by Western blotting. Samples as in (**B**). Tubulin used as a loading control. (**D**) Brain metastasis free survival in a cohort of 368 untreated breast cancer patients. Cases classified based on *RBM47* mRNA expression, bottom 1/3 in blue, top 2/3 in red. p-value derived from a Cox proportional hazards model using *RBM47* expression as a continuous variable. (**E**) Lung metastasis free survival in a cohort of 368 untreated breast cancer patients. Cases classified based on *RBM47* mRNA expression, bottom 1/3 in blue, top 2/3 in red. p-value derived from a Cox proportional hazards model using *RBM47* expression as a continuous variable. (**F**) Bone metastasis free survival in a cohort of 368 untreated breast cancer patients. Cases classified based on *RBM47* mRNA expression, bottom 1/3 in blue, top 2/3 in red. p-value derived from a Cox proportional hazards model using *RBM47* expression as a continuous variable.(**G**) RBM47 expression as measured by RNA-seq in the TCGA data set of 748 patients. Samples grouped based on breast cancer molecular subtype: luminal A, luminal B, Her2 positive, claudin low and basal. RBM47 expression is lower in claudin low and basal subtypes, both of which are associated with poor patient outcome. (**H**) A schematic showing the predicted protein structure of RBM47, its closest homologue A1CF, a known RNA-binding protein, and the predicted structure of RBM47^I281fs^ mutant. Blue diamonds represent RRM motifs, pink rectangle represents a truncated RRM motif.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.003](10.7554/eLife.02734.003)10.7554/eLife.02734.004Figure 1---figure supplement 1.*RBM47* expression and genetic alterations in human breast cancer.(**A**) Multivariate Cox proportional hazards models for both brain and lung metastasis free survival in a cohort of 368 untreated breast cancer patients. The model incorporates *RBM47* expression as a continuous variable, estrogen receptor (ER) expression, progesterone receptor (PR) expression and Her2 expression. (**B**) A list of protein-altering *RBM47* breast cancer mutations in the Catalogue of Somatic Mutations in Cancer database (COSMIC, <http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>) as of June 2013. (**C**) Percentage of genetic alterations, non-synonymous mutations or homozygous deletions, in *RBM47* in the TCGA cohort of 748 breast cancers classified based on molecular subtypes: luminal A, luminal B, Her2 positive, claudin low and basal. A significant enrichment is observed in the basal subtype (p=0.00015, Fisher\'s exact test).**DOI:** [http://dx.doi.org/10.7554/eLife.02734.004](10.7554/eLife.02734.004)

The *RBM47*^*I281fs*^ mutation first reported in a brain metastasis truncates the protein from the third RNA recognition motif (RRM) onwards ([Figure 1H](#fig1){ref-type="fig"}). As this mutation was already present in a minority subpopulation of the corresponding primary tumor ([@bib21]), we looked for additional evidence of genetic *RBM47* aberrations in primary breast cancer cohorts. The catalogue of somatic mutations in cancer (COSMIC) database ([@bib26]) reported 9 non-synonymous mutations in *RBM47*, three of which were frameshift mutations truncating one or more of the RRM domains ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Furthermore, analysis of the data from the TCGA cohort revealed that in basal breast cancer, *RBM47* was targeted by a mutation or homozygous deletion in ∼8% of the cases ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Moreover, heterozygous loss of the *RBM47* locus was present in 30% of the TCGA cohort ([@bib9]). These correlative analyses of multiple different breast cancer data sets, both experimental systems and large clinical patient cohorts, suggested that reduced expression or function of RBM47 is associated with breast cancer progression already within primary tumors, and that clones with reduced RBM47 function may display enhanced lung and brain metastatic fitness.

RBM47 suppresses breast cancer progression {#s2-2}
------------------------------------------

In order to test the role of *RBM47* as a suppressor of breast cancer progression, we stably introduced both wild type *RBM47* and *RBM47*^*I281fs*^ in the lung metastatic (LM2) and brain metastatic (BrM2) derivatives of the MDA-MB-231 triple negative breast cancer cells (MDA231 for short), respectively ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}; [@bib46]; [@bib7]). Of note, despite robust mRNA expression, the mutant RBM47^I281fs^ protein levels were low, indicating that the mutant protein was unstable and therefore inactive ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). As determined by in vivo bioluminescence in experimental metastasis assays, wild type *RBM47* inhibited lung colonization by the MDA231-LM2 cells, when compared to *RBM47*^*I281fs*^ ([Figure 2A--B](#fig2){ref-type="fig"}). Similarly, we observed extended brain metastasis free survival in mice inoculated with the MDA231-BrM2 cells expressing *RBM47* when compared to those expressing *RBM47*^*I281fs*^ ([Figure 2C](#fig2){ref-type="fig"}). This difference translated into reduced brain metastatic burden as determined by ex vivo imaging ([Figure 2D,E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). We then tested the effects of inhibiting endogenous RBM47 in the metastatic colonization of the parental MDA231 cells. With comparable effects of RBM47 re-expression seen in both the lung and brain metastasis models ([Figure 2A,E](#fig2){ref-type="fig"}), we chose the lung colonization assay for loss-of-function studies as this allowed the simultaneous analysis of a greater number of tumor re-initiation events. Two *RBM47*-targeting shRNA constructs significantly shortened the lung metastasis free survival in mice when compared to controls ([Figure 2F](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}), as determined by bioluminescence imaging ([Figure 2G,H](#fig2){ref-type="fig"}). This result was confirmed with a second more indolent cancer cell clone ([Figure 2---figure supplement 1E--G](#fig2s1){ref-type="fig"}).10.7554/eLife.02734.005Figure 2.RBM47 suppresses metastatic breast cancer progression.(**A**) Normalized lung photon flux in mice after tail vein inoculation of MDA231-LM2 cells expressing either wild type *RBM47* or *RBM47*^*I281fs*^. p-value calculated utilizing repeated measures two-way ANOVA. N = 6 for *RBM47*^*I281fs*^, N = 8 for *RBM47*. (**B**) Representative bioluminescence images from the experiment shown in (****A****). The color scale shows bioluminescence (photons/second). (**C**) Brain metastasis free survival as determined by in vivo bioluminescence imaging in mice after intracardiac inoculation of MDA231-BrM2 cells expressing either wild type *RBM47* or *RBM47*^*I281fs*^. p-value calculated using the log-rank test. N = 9 for *RBM47*^*I281fs*^, N = 7 for *RBM47*. (**D**) Representative bioluminescence images from the experiment shown in (**C**). The color scale shows bioluminescence (photons/second). (**E**) Ex vivo quantification of bioluminescence from brain metastases on day 42 of the experiment shown in panel (**C**). P-value calculated by two-tailed Student\'s *t* test. (**F**) Lung metastasis free survival as determined by in vivo bioluminescence imaging in mice after tail vein inoculation of parental MDA231 cells expressing either control vector (pGIPZ) or hairpins against RBM47 (shRNA1 and shRNA2). p-values calculated using the log-rank test. N = 8 for Ctrl group, N = 6 for shRNA1, N = 5 for shRNA2. (**G**) In vivo bioluminescence imaging on day 36 of the experiment shown in (****F****) demonstrates earlier emergence of detectable lung metastasis for the RBM47 knockdown groups when compared to the control animals. The color scale shows bioluminescence (photons/second). (**H**) Quantification of bioluminescence for the time point shown in (****G****). Data normalized to signal on day 0 for each animal. p-value calculated using the Wilcoxon rank-sum test.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.005](10.7554/eLife.02734.005)10.7554/eLife.02734.006Figure 2---figure supplement 1.RBM47 suppresses breast cancer progression.(**A**) *RBM47* mRNA expression measured by quantitative real-time RT-PCR in 231-BrM2 and 231-LM2 cells transduced with either wild type *RBM47* or *RBM47*^*I280fs*^-expressing cDNA constructs, respectively. The data are normalized to the untransduced control cell lines. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**B**) Flag-RBM47 protein expression determined by Western blotting in non-clonal 231BrM2 tet-on Flag-RBM47 cells. No RBM47 or Flag protein is detected in the cells expressing Flag-RBM47^I281fs^ (predicted size 34 kDa) treated with the same doxycycline doses. (**C**) Quantification of bioluminescence from the head of mice on day 0 of the experiment shown in [Figure 2C](#fig2){ref-type="fig"}. p-value calculated by two-tailed Student\'s *t* test. (**D**) RBM47 mRNA and protein expression measured by quantitative real-time RT-PCR and Western blotting, respectively, in parental MDA-231 cells expressing either control vector (pGIPZ) or hairpins against *RBM47* (shRNA1 and shRNA2). Error bars represent 95% confidence intervals obtained from multiple PCR reactions. Tubulin used as a protein loading control. (**E**) RBM47 mRNA and protein expression measured by quantitative real-time RT-PCR and Western blotting, respectively, in parental CN34 cells expressing either control vector (pGIPZ) or hairpins against *RBM47* (shRNA1 and shRNA2). Error bars represent 95% confidence intervals obtained from multiple PCR reactions. Tubulin used as a protein loading control. (**F**) Quantification of lung metastatic burden on day 0 by in vivo bioluminescence imaging in mice after tail vein inoculation of parental CN34 cells expressing either control vector (pGIPZ) or hairpins against RBM47 (shRNA1 and shRNA2). p-values calculated using two-sided Student\'s *t* test. N = 5 for all groups. (**G**) Quantification of lung metastatic burden on day 141 by in vivo bioluminescence imaging in mice after tail vein inoculation of parental CN34 cells expressing either control vector (pGIPZ) or hairpins against RBM47 (shRNA1 and shRNA2). p-values calculated using two-sided Student\'s *t* test. N = 4 for Ctrl group, N = 5 for shRNA1, N = 4 for shRNA2.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.006](10.7554/eLife.02734.006)

Clonal heterogeneity in RBM47 sensitivity {#s2-3}
-----------------------------------------

The initial functional experiments suggested that the tumor suppressive effect of RBM47 on the overall population of metastatic cancer cells was modest. This could reflect either weak tumor suppressive function of RBM47 in general, heterogeneity in the sensitivity to RBM47 among different cancer cell subpopulations, or in the case of RBM47 reintroduction, loss of transgene expression. In order to distinguish between these possibilities, we used immunohistochemistry to assess RBM47 expression in the lung nodules formed either by wild type *RBM47* or *RBM47*^*I281fs*^ expressing cells. This revealed that some cancer clones were able to form robust lung metastasis even in the presence of RBM47 ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), but that many of the metastases formed after the inoculation of wild type RBM47-expressing cells had avoided or suppressed the expression of RBM47 ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3A---figure supplement 1A](#fig3s1){ref-type="fig"}). As expected, the *RBM47*^*I281fs*^-expressing tumors contained only weakly staining cancer cells intermingled with small cells with strong RBM47 expression ([Figure 3C](#fig3){ref-type="fig"}), similar to those seen in normal lung parenchyma ([Figure 3D](#fig3){ref-type="fig"}). The rate of proliferation as determined by Ki67 immunohistochemistry did not correlate with the level of RBM47 expression ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). This was in line with the idea that some clones were more sensitive to RBM47 than others, but also that a strong selective pressure led metastatic cells to lose RBM47, a finding consistent with the initial observation of RBM47 loss in metastatic cell populations ([Figure 1C](#fig1){ref-type="fig"}).10.7554/eLife.02734.007Figure 3.Clonal heterogeneity in RBM47 sensitivity.(**A**) A lung metastatic nodule with strong RBM47 expression in a mouse inoculated with RBM47-transduced MDA231-LM2 cells. RBM47 protein expression detected by immunohistochemistry using an antibody against RBM47. (**B**) A lung metastatic nodule with weak RBM47 expression in a mouse inoculated with RBM47-transduced MDA231-LM2 cells. RBM47 protein expression detected by immunohistochemistry. Note the clearly reduced staining when compared to panel (**A**). (**C**) A lung metastatic nodule with weak RBM47 expression in a mouse inoculated with *RBM47*^*I280fs*^-transduced MDA231-LM2 cells. RBM47 protein expression detected by immunohistochemistry. Staining intensity similar to that seen in panel (**B**). (**D**) RBM47 expression in normal mouse lung. RBM47 protein expression detected by immunohistochemistry. Note small cells with strong RBM47 expression, similar to those seen in panels (**B**) and (**C**). (**E**) Brain metastasis free survival as determined by in vivo bioluminescence imaging in mice after intracardiac inoculation of WT10 cells. The RBM47 group received doxycycline in diet. p-value calculated using the log-rank test. N = 9 for both groups. (**F**) Representative ex vivo bioluminescence images from brain metastasis of the experiment shown in (**E**). The color scale shows bioluminescence (photons/second). (**G**) Ex vivo quantification of bioluminescence from brain metastases with and without RBM47 reintroduction. WT10 data from the experiment shown in (**E**). WT6 data from a similar experimental setup. p-value calculated by two-tailed Student\'s *t* test. N = 9 for Ctrl group, N = 10 for RBM47 group. (**H**) Brain metastasis free survival as determined by in vivo bioluminescence imaging in mice after intracardiac inoculation of MUT3 cells. The I281fs group received doxycycline in diet. p-value calculated using the log-rank test. N = 9 for Ctrl group, N = 7 for RBM47^I281fs^ group. (**I**) Representative ex vivo bioluminescence images from brain metastases of the experiment shown in (**H**). The color scale shows bioluminescence (photons/second). (**J**) Ex vivo quantification of bioluminescence from brain metastases of the experiment shown in (**H**). p-value calculated by two-tailed Student\'s *t* test.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.007](10.7554/eLife.02734.007)10.7554/eLife.02734.008Figure 3---figure supplement 1.RBM47 expression in experimental metastases.(**A**) Examples of lung metastatic nodules in a mouse inoculated with RBM47-transduced 231-LM2 cells. Some metastases have strong expression of RBM47 (left), whereas others show only weak RBM47 expression (right). Staining against human vimentin and Ki67 is shown for the same lesions.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.008](10.7554/eLife.02734.008)10.7554/eLife.02734.009Figure 3---figure supplement 2.Model systems with inducible RBM47 expression.(**A**) *RBM47* mRNA expression measured by quantitative real-time RT-PCR in WT6 cells treated with increasing concentrations of doxycycline. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**B**) *RBM47* mRNA expression measured by quantitative real-time RT-PCR in WT10 cells treated with increasing concentrations of doxycycline. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**C**) *RBM47* mRNA expression measured by quantitative real-time RT-PCR in MUT3 cells treated with increasing concentrations of doxycycline. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**D**) RBM47 protein expression detected by Western blotting in WT6 cells treated with increasing concentrations of doxycycline. ACTB used as a loading control. Quantification of signal shown in the lower panel, normalized to both ACTB loading control and the level of endogenous RBM47 detected in HCC1954 cells. (**E**) RBM47 protein expression detected by Western blotting in WT10 cells treated with increasing concentrations of doxycycline. ACTB used as a loading control. Quantification of signal shown in the lower panel, normalized to both ACTB loading control and the level of endogenous RBM47 detected in HCC1954 cells. (**F**) Proliferation of WT6 cells assessed under standard tissue culture conditions with and without doxycycline (2.5 ng/ml). (**G**) Demonstration of doxycycline-inducible gene induction in brain metastatic lesions formed by 231-BrM2 cells transduced with an inducible RFP construct. Cancer cells express constitutively GFP. Doxycycline treatment started on day 14 after intracardiac cancer cell inoculation. Doxycycline-inducible RFP expression can be seen in cancer cells.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.009](10.7554/eLife.02734.009)

In order to allow better experimental control over RBM47 expression we utilized a conditional expression system. By focusing on the two brain metastatic cell lines that expressed the lowest levels of endogenous RBM47 ([Figure 1C](#fig1){ref-type="fig"}) we generated single cell-derived clones with doxycycline-inducible expression of either wild type RBM47 (henceforth WT10 and WT6, respectively) or the patient-derived mutant RBM47^I281fs^ (henceforth MUT3). All clones exhibited dose-dependent RBM47 mRNA upregulation upon doxycycline induction ([Figure 3---figure supplement 2A--C](#fig3s2){ref-type="fig"}) that translated into increased RBM47 protein expression in the wild type-expressing clones ([Figure 3---figure supplement 2D,E](#fig3s2){ref-type="fig"}). Cancer cells also tolerated RBM47 in vitro ([Figure 3---figure supplement 2F](#fig3s2){ref-type="fig"}). After confirming the feasibility of doxycycline-mediated conditional gene activation in metastatic brain lesions ([Figure 3---figure supplement 2G](#fig3s2){ref-type="fig"}), we inoculated WT6, WT10 and MUT3 cells into immunocompromized mice and assessed their brain-metastatic phenotype. All clones formed robust brain metastases under doxycycline-free conditions ([Figure 3E--J](#fig3){ref-type="fig"}). The induction of *RBM47* expression with doxycycline in the diet inhibited robustly brain colonization of both metastatic cell clones, WT6 and WT10 ([Figure 3E--G](#fig3){ref-type="fig"}). However, the patient-derived mutant *RBM47*^*I281fs*^ did not show any tumor suppressive effects ([Figure 3H--J](#fig3){ref-type="fig"}). Collectively, these results demonstrated that RBM47 was able to strongly inhibit metastatic functions of some cancer clones, whereas other clones were able to form metastasis despite the presence of RBM47.

Transcriptome-wide identification of RBM47 binding sites {#s2-4}
--------------------------------------------------------

To determine whether RBM47 can directly bind RNA in vivo, we made use of the ability of UV-irradiation at 254 nm to induce chemical crosslinks between RNA and proteins that are in direct contact ([@bib18]). γ-^32^P-labeled RNA was detected by autoradiogram at ∼76 kD, the predicted size of Flag-RBM47, in Flag-immunoprecipitates from UV-irradiated, doxycycline-treated MDA231-BrM2 WT Flag-RBM47 cells, but not doxycycline-treated empty vector control or non-irradiated WT Flag-RBM47 expressing cells ([Figure 4A](#fig4){ref-type="fig"}). To identify directly bound RBM47 targets, a modified version of the high throughput sequencing and cross-linking immunoprecipitation (HITS-CLIP) protocol ([@bib39]; [@bib73]) was carried out in duplicate on Flag-RBM47 expressing MDA231-BrM2 cells treated with doxycycline. ([Figure 4B](#fig4){ref-type="fig"}, see \'Materials and methods\'). RBM47-bound HITS-CLIP reads were mapped to the human genome, yielding ∼7.7 × 10^6^ and ∼2.0 × 10^6^ unique reads (tags) per replicate. 75% of the tags mapped to regions corresponding to UCSC/Refseq genes, with a high degree of reproducibility of binding observed between replicates (Spearmann correlation coefficient R^2^ = 0.998, total tags per gene, [Figure 4C](#fig4){ref-type="fig"}).10.7554/eLife.02734.010Figure 4.HITS-CLIP identifies genome-wide RBM47 binding maps.(**A**) Radiolabelled RNA is detectable in RBM47-expressing 231-BrM2 metastatic cells that have been UV-irradiated indicating in vivo RNA binding ability. No RNA is detected in non-crosslinked cells despite the presence of ample immunoprecipitated Flag-RBM47 protein. No RNA or protein is detected in control 231-BrM2 transduced with empty vector. Samples run in duplicate. (**B**) Schematic of the modified HITS-CLIP protocol showing autoradiogram of duplicate Flag-RBM47 samples used. Purified RBM47-bound RNA fragments (green) were polyA tailed and reverse transcribed in the presence of Brd-U using a polydT-NV primer encoding the full sense sequence of the Illumina reverse sequencing primer (blue), an abasic furan that serves as an ApeI cut site (ξ), a partial reverse complement to the Illumina forward sequencing primer (orange), and two hexamer sequences (purple): a known-sequence index for multiplexing and a degenerate barcode used to distinguish unique cDNA clones from PCR duplicates. cDNA were stringently purified, circularized and linearized using ApeI to bring the Illumina sequence into correct orientation with respect to the cloned fragment, and the samples PCR amplified and deep sequenced. (**C**) RBM47 HITS-CLIP is highly reproducible between replicate experiments at the level of unique CLIP tags per transcript. (**D**) Increasing the stringency of biologically reproducible RBM47 binding site definition reveals predominant binding in 3′UTRs and intronic regions of target transcripts, with the most robust binding (tags per binding site) evident in 3′UTRs. (**E**) Distribution of tags number per biologically reproducible cluster in coding and non-coding regions of RBM47-targeted transcripts reveals a bimodal binding pattern between 3′UTRs and introns, with the latter having large numbers of reproducible yet less robust binding. (**F**) MEME analysis reveals an enrichment for polyU sequences (50 sites, p=2.4e^−16^) in the ±10 nt foot print region surrounding reproducible RBM47 deletion CIMS (357 sites with ≥5 mutations, FDR ≤0.01, [@bib75]). (**G**) Widespread RBM47 binding is seen in target transcripts, as exemplified by binding patterns seen in the 3′UTRs of DKK1 and IL8.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.010](10.7554/eLife.02734.010)

To identify robust and reproducible RBM47-binding sites, tags were clustered to return regions with evidence of binding in both replicates (biological complexity, BC = 2) with increasingly stringent filters ([Figure 4D](#fig4){ref-type="fig"}): tags per cluster (tags ≥2, 617,026 clusters; tags ≥10, 94,966 clusters), a previously described significant peak threshold (significant peak height ≥10, 29,562 clusters \[[@bib13]\]), and a ranked reproducibility chi-squared score (p≤0.01, 19,433 clusters \[[@bib17]\]). As has been previously described for the n-ELAV proteins ([@bib30]), identification of the most robust binding through increased stringency of cluster definition led to an increase in proportional binding in 3′UTR regions. For RBM47 this occurred due to loss of the majority of reproducible, yet relatively small intronic binding sites ([Figure 4E](#fig4){ref-type="fig"}), which may reflect the relative abundance of pre- and mature RNA message. Motif analysis (MEME, [@bib3]) failed to identify an enriched RBM47-binding sequence in ±10 nt footprints centered on the top 3000 significant peaks (data not shown), but revealed a polyU sequence enriched in RBM47-binding sites containing cross-link induced mutations (deletion CIMS, [@bib75], [Figure 4F](#fig4){ref-type="fig"}). The apparent lack of an enriched RBM47-binding motif within robust CLIP-derived binding sites may reflect the broad binding patterns observed, as exemplified by the predominantly 3′UTR binding in *DKK1* and *IL8* ([Figure 4G](#fig4){ref-type="fig"}).

RBM47 regulates alternative splicing {#s2-5}
------------------------------------

Reproducible binding of RBPs in intronic regions has proven to be predictive of a role in pre-mRNA processing for multiple proteins. To explore the relationship between RBM47 intronic binding and alternative splicing, RNA-seq was carried out in triplicate to compare MDA231-BrM2 cells and RBM47-expressing WT10 cells. Reads were mapped to cassette (CA) exon junctions as described previously for Mbnl2 ([@bib10]), and an average inclusion rate (IR) calculated for each cell type to allow for the identification of reciprocal splicing changes while normalizing for changes in RNA stability ([@bib66]; [Figure 5A](#fig5){ref-type="fig"}). The average change in inclusion rate (ΔI) was then calculated such that positive ΔI indicates RBM47-dependent cassette exon inclusion. This analysis revealed 121 and 140 CA exons with significant RBM47-dependent inclusion and exclusion, respectively. To assess whether RBM47-binding occurred in the vicinity of these splice sites, HITS-CLIP tags in BC2 tags ≥5 clusters (to account for lower levels of intronic binding seen in [Figure 4E](#fig4){ref-type="fig"}) in the region of the alternative splice were calculated. Forty-eight RBM47-bound included and 49 RBM47-bound excluded CA exons were identified in a total of 84 genes ([Figure 5B](#fig5){ref-type="fig"}; [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). RBM47-dependent splicing changes were confirmed via RT-PCR as shown for *SLK*, *MDM4*, *LIMCH1*, *MBNL1* and *SEC31A* ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).10.7554/eLife.02734.011Figure 5.RBM47 regulates alternative splicing.(**A**) Schematic showing the method used to calculate alternative exon inclusion rates from paired-end RNA-seq data. 5′CE--5′ flanking constitutive exon, 3′CE--3′ flanking constitutive exon, 5′FI--5′ Flanking intron, 3′FI--3′ Flanking intron. (**B**) Scatter plot of all expressed alternatively spliced CA exons showing RBM47-dependent change in inclusion (black, ≥10 RNA-seq reads spanning exon--exon junctions, ΔI ≥\|0.2\|, p≤0.05) with orange points indicating RBM47-bound and included CA exons, and blue points indicating bound and excluded exons, respectively. CA exons were considered bound given a total of tags ≥10 in BC2 tags ≥5 clusters mapping to the region spanning the start of the 5′CE to the end of the 3′CE. p-values calculated by Fisher\'s exact test using total isoform 1 and total isoform 2 RNA-seq reads in each condition. (**C**) Left panel shows a section of the SLK transcript (blue) that includes a CA exon (grey box). The top two panels show RNA-seq data from WT10 (green) and control cells (red), with RBM47 HITS-CLIP tags mapping to the region shown beneath in black. Increased RNA-seq signal corresponding to the CA exon is seen in the presence of RBM47 expression, while robust binding is evident in the 5′FI. Independent RT-PCR validation of this splice is shown in the right panel, with IR calculated using ImageJ analysis of autoradiograms. (**D**) Normalized complexity map of RBM47-dependent alternative splicing of CA exons. Orange and blue peaks represent binding associated with RBM47-dependent exon inclusion and exclusion, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.011](10.7554/eLife.02734.011)10.7554/eLife.02734.012Figure 5---figure supplement 1.RBM47-dependent splicing events.(**A**) RBM47-dependent exclusion of exon 6 of MDM4, as in [Figure 5C](#fig5){ref-type="fig"}. (**B**) RBM47-dependent exclusion of a CA in LIMCH1, as in [Figure 5C](#fig5){ref-type="fig"}. (**C**) RBM47-dependent inclusion of exon 5 in MBNL1, as in [Figure 5C](#fig5){ref-type="fig"}. (**D**) RBM47-dependent inclusion of two CA exons in SEC31A, as in [Figure 5C](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.012](10.7554/eLife.02734.012)

By mapping normalized RBM47 CLIP tags associated with RBM47-dependent splicing changes on a composite transcript ([@bib39]) we generated an RNA binding map of consensus binding sites within 1 kb of exon-intron boundaries, with respect to exon inclusion or exclusion ([Figure 5D](#fig5){ref-type="fig"}). The resulting normalized complexity map reveals enriched RBM47 binding in the vicinity of splice acceptor sites of the CA exon and 3′ CE for included alternative isoforms, while relative enrichment of RBM47 binding was seen at the 5′ CE splice donor and 3′CE splice acceptor of excluded isoforms.

RBM47 affects mRNA steady state levels {#s2-6}
--------------------------------------

To further study the functional consequences of RBM47-mRNA binding events, we determined global steady state mRNA levels in the RBM47 expressing brain metastatic cells by RNA-seq. We took advantage of the clonal doxycycline-inducible cell line systems, which facilitated the analysis of RBM47 dose-dependence. First, genome-wide analyses showed that the mRNA level of several more genes correlated significantly with increasing concentrations of doxycycline in both cell lines expressing the wild type RBM47 (WT6 and WT10), when compared to cells expressing the mutant ([Figure 6A](#fig6){ref-type="fig"}). This result indicated that RBM47 elicits dose-dependent changes in mRNA levels. The correlation coefficients followed a pattern that suggested the existence of mRNA species that correlated both positively and negatively with wild type, but not mutant, RBM47 expression, that is few genes in MUT3 cells had correlation coefficients close to 1 or −1, whereas in WT6 and WT10 cells such genes were abundant ([Figure 6B](#fig6){ref-type="fig"}). Encouraged by these observations, we looked for mRNAs that fulfilled the following criteria: (i) p-value of correlation less than 0.01 in both WT6 and WT10 cells, (ii) mRNA expression change detectable already at the lowest levels of RBM47 expression in both cell clones and (iii) no significant correlation with RBM47^I281fs^ expression. This revealed a set of 102 mRNAs that were upregulated and 92 that were downregulated, respectively, in cells expressing the wild type RBM47 ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}; [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Importantly, these changes were observed already with the lowest expression level of RBM47 that was comparable or lower than those detected in endogenously RBM47 expressing cells ([Figure 3---figure supplement 2D,E](#fig3s2){ref-type="fig"}).10.7554/eLife.02734.013Figure 6.RBM47-induced changes in mRNA levels.(**A**) Distribution of p-values from correlation analysis of doxycycline concentration and gene expression for all genes in WT6, WT10 and MUT3 cell lines, respectively. Global gene expression determined by RNA-seq. (**B**) Distribution of correlation coefficients between doxycycline concentration and gene expression in WT6, WT10 and MUT3 cell lines, respectively. (**C**) Heat maps showing the top 102 positively (UP) correlated and 92 negatively (DOWN) correlated genes with RBM47 expression in WT6 and WT10 cells. The expression of these genes does not correlate with *RBM47*^*I280fs*^ expression in the MUT3 cells. (**D**) *RBM47* mRNA expression in the TCGA cohort of breast cancer samples classified by the clusters shown in [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}. p-value determined by two-tailed Student\'s *t* test. (**E**) Fold change between Cluster 1 and Cluster 2 shown for the 102 positively and 92 negatively correlated RBM47 target genes, respectively. Positive fold change shows higher expression in Cluster 2, which has lower expression of RBM47. The genes that are induced upon RBM47 reintroduction tend to have lower expression in Cluster 2, and the genes that show lower expression upon RBM47 reintroduction tend to have higher expression in Cluster 2. This is in line with the experimental results shown in panel (**C**). P-value determined by two-tailed Student\'s *t* test. (**F**) Pie charts showing the fraction of target genes with more than 100 RBM47 tags for both the 102 positively and 92 negatively correlated RBM47 target genes. (**G**) Tags per transcript plotted for both the positively and negatively correlated RBM47 target genes that showed more than 1 tag. The only two binding partners with \>10^4^ tags represent *DKK1* and *IL8*, respectively. (**H**) Secreted DKK1 and IL8 protein levels determined by ELISA in WT6 cells treated with the indicated doxycycline concentrations. VEGFA used as a control.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.013](10.7554/eLife.02734.013)10.7554/eLife.02734.014Figure 6---figure supplement 1.Transcriptomic signature of RBM47 reintroduction.(**A**) Normalized average RNA-seq reads per transcript for the 102 positively correlated RBM47 target genes shown for WT6, WT10 and MUT3 cells treated with the indicated doxycycline concentrations. (**B**) Normalized average counts for the 92 negatively correlated RBM47 target genes shown for WT6, WT10 and MUT3 cells treated with the indicated doxycycline concentrations. (**C**) A heatmap showing unsupervised hierarchical clustering in the TCGA cohort of 748 samples using the 194 RBM47 target genes identified by RNA-seq. Two main clusters are detected.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.014](10.7554/eLife.02734.014)

To determine whether the 194 RBM47-responsive genes displayed clinically meaningful expression patterns, we conducted an unsupervised hierarchical clustering analysis of the TCGA cohort of breast cancer specimens. Two main clusters emerged, one of which harbored characteristics of the RBM47-low phenotype ('Cluster 2', [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). First, this subgroup, Cluster 2, had significantly lower RBM47 expression levels when compared to Cluster 1 ([Figure 6D](#fig6){ref-type="fig"}). Second, the genes that were induced upon RBM47 reintroduction tended to have lower expression in Cluster 2, whereas genes with reduced expression level in the RBM47-expressing cells tended to show higher expression in Cluster 2 ([Figure 6E](#fig6){ref-type="fig"}). These observations validated in clinical tumor samples the RBM47-dependent gene expression correlations identified in vitro.

To identify directly regulated targets of RBM47, we combined the mRNA expression data with the HITS-CLIP-derived RBM47 transcriptome-wide binding data. Of the 2498 strongest binding partners with \>100 tags per transcript (total tags in BC2 tags ≥10 clusters; [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}), 25 were among the 102 RBM47-upregulated genes and 17 among the 92 RBM47-downregulated genes ([Figure 6F](#fig6){ref-type="fig"}), indicating no significant binding preference for either groups. This was reflected in the similar overall RBM47 binding profiles in both the up- and down-regulated genes ([Figure 6G](#fig6){ref-type="fig"}). Two of the top-scoring RBM47 binding mRNAs, *IL8* and *DKK1* (17,079 and 16,208 tags in clusters per gene, respectively, [Figure 4G](#fig4){ref-type="fig"}), were among the upregulated genes. This increase in mRNA levels was associated with increased protein secretion as determined by ELISA, whereas VEGFA, the mRNA of which was bound but not upregulated by RBM47, showed no change in protein secretion ([Figure 6H](#fig6){ref-type="fig"}).

RBM47 modulates *DKK1* mRNA stability {#s2-7}
-------------------------------------

Nuclear RNA binding proteins typically function in large multiprotein complexes that regulate mRNA biogenesis ([@bib24]). Our data from both genome-wide HITS-CLIP and RNA-seq analysis was compatible with RBM47 being a member of these RNA chaperone units. This suggested that RBM47 may not necessarily have a direct tumor suppressive signaling function. Rather, it raised the possibility that loss of RBM47, leading to subtle changes in multiple mRNAs, either through stabilization, destabilization or alternative splicing, could be selected for if the net effect of both growth-promoting and growth-inhibiting changes would be beneficial for cancer cells under the stress of dissemination to and colonizing distant organs. In line with this, both the up- and down-regulated target genes of RBM47, as well as the genes that were targets of RBM47-mediated alternative splicing, contain genes that have previously been shown to either promote or inhibit tumor phenotypes ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"} and [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}). For example, *DKK1* ([@bib2]; [@bib16]; [@bib45]), *HTATIP2* ([@bib77]), *HBP1* ([@bib52]; [@bib36]), *MXI1* ([@bib35]) and *CASP7* ([@bib29]), all bound by RBM47 and upregulated upon RBM47 reintroduction, have known tumor suppressive functions. Similarly, RBM47-induced splicing changes were seen in genes such as *SLK* ([@bib56]), *MDM4* ([@bib69]) and *TNC* ([@bib51]), all of which are genes with known functions in cancer.

Focusing on *DKK1*, one of the most robustly bound RBM47 target transcripts identified by HITS-CLIP, we investigated the possible role of RBM47 as a modulator of mRNA abundance. As predicted by our results in WT6 and WT10 cells, knockdown of RBM47 in two additional breast cancer cell lines expressing high levels of endogenous RBM47, SKBR3 and ZR-75-30, reduced *DKK1* mRNA levels ([Figure 7A](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). This validated RBM47 as a modulator of *DKK1* mRNA level in breast cancer cells.10.7554/eLife.02734.015Figure 7.RBM47 modulates *DKK1* mRNA stability.(**A**) *RBM47* and *DKK1* mRNA expression measured by quantitative real-time RT-PCR in SKBR3 cells expressing either control vector (pGIPZ) or hairpins against *RBM47* (shRNA1 and shRNA2). Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**B**) *DKK1* mRNA stability determined by measuring mRNA levels by quantitative real-time RT-PCR in WT6, WT10 and MUT3 cells, treated with or without doxycycline, after inhibition of transcription with actinomycin D. Data normalized to time point 0. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. WT6: T~1/2~ Ctrl = 2.3 hr, T~1/2~ Dox = 9.8 hr; WT10: T~1/2~ Ctrl = 2.4 hr, T~1/2~ Dox = 5.4 hr; MUT3: T~1/2~ Ctrl = 2.1 hr, T~1/2~ Dox = 2.2 hr. (**C**) Schematic showing the locations of different DKK1 miR-constructs in relation to *DKK1* genomic locus and RBM47 binding patterns. miRm and miRn target exon 1 that is not bound by RBM47. miRo, miRp and miRq target *DKK1* 3′UTR that is strongly bound by RBM47. (**D**) *DKK1* mRNA expression measured by quantitative real-time RT-PCR in WT6 cells expressing either control vector (pGIPZ) or the five *DKK1-*targeting miR constructs shown in panel (****C****). Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**E**) *DKK1* mRNA expression measured by quantitative real-time RT-PCR in WT6 cells expressing either control vector (pGIPZ) or the five *DKK1-*targeting miR constructs, with or without doxycycline treatment. Data normalized to the non-treated control for each cell line separately. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**F**) *DKK1* mRNA expression measured by quantitative real-time RT-PCR in WT10 cells expressing either control vector (pGIPZ) or the five *DKK1-*targeting miR constructs shown in panel (****C****). Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**G**) *DKK1* mRNA expression measured by quantitative real-time RT-PCR in WT10 cells expressing either control vector (pGIPZ) or the five *DKK1-*targeting miR constructs, with or without doxycycline treatment. Data normalized to the non-treated control for each cell line separately. Error bars represent 95% confidence intervals obtained from multiple PCR reactions.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.015](10.7554/eLife.02734.015)10.7554/eLife.02734.016Figure 7---figure supplement 1.Effects of RBM47 knockdown on *DKK1* mRNA.(**A**) *RBM47* and *DKK1* mRNA expression measured by quantitative real-time RT-PCR in ZR-75-30 cells expressing either control vector (pGIPZ) or a hairpin against *RBM47* (shRNA2). Error bars represent 95% confidence intervals obtained from multiple PCR reactions.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.016](10.7554/eLife.02734.016)

The fact that RBM47 bound to *DKK1* mRNA 3′UTR and increased *DKK1* mRNA levels suggested the possibility that RBM47 had the capability of stabilizing *DKK1* mRNA. We tested this by treating cancer cells with actinomycin D, a general inhibitor of transcription, and measuring *DKK1* mRNA levels in the following hours. This demonstrated that wild type *RBM47*, but not the *RBM47*^*I281fs*^ mutant, was able to increase the half-life of *DKK1* mRNA by up to fourfold ([Figure 7B](#fig7){ref-type="fig"}).

RBM47 protects *DKK1* 3′UTR from destabilizing factors {#s2-8}
------------------------------------------------------

As RBM47 binding to *DKK1* was concentrated on the 3′UTR, a known region of regulatory activity ([@bib78]), we considered the possibility that RBM47 could compete with microRNAs or other mRNA destabilizing factors that target the 3′UTR ([@bib6]; [@bib74]). To test this experimentally, we generated miR-30-based shRNA-miR constructs that targeted different regions of the *DKK1* transcript, two at the 5′ end with minimal RBM47 binding and three at the 3′ end with abundant RBM47 signal ([Figure 7C](#fig7){ref-type="fig"}; [@bib25]). All constructs knocked the *DKK1* transcript level down by 65--80% in the WT6 cells when no doxycycline was present ([Figure 7D](#fig7){ref-type="fig"}). The induction of RBM47 expression did not have a significant effect on the efficiency on the 5′-targeting shRNA-miRs ([Figure 7E](#fig7){ref-type="fig"}). In contrast, RBM47 inhibited the capability of the 3′-targeting shRNA-miRs to keep the *DKK1* mRNA level down ([Figure 7E](#fig7){ref-type="fig"}). Similar observations were made with the WT10 cells ([Figure 7F,G](#fig7){ref-type="fig"}). Argonaute HITS-CLIP in the MDA231-BrM2 cells (CBM et al., unpublished data) indicates robust binding to the DKK1 3′UTR, supporting the regulatory role of this region. We conclude that the effects of RBM47 on *DKK1* mRNA levels may be due to the ability of RBM47 to protect this mRNA from destabilizing factors, possibly through direct interaction with the *DKK1* mRNA.

RBM47 inhibits tumor progression by suppressing Wnt activity {#s2-9}
------------------------------------------------------------

DKK1 is an inhibitor of Wnt signaling, a pathway with a well-established role in regulating stem cell characteristics in both normal and malignant cells ([@bib14]). Indeed, DKK1 as well as other Wnt antagonists have been shown to inhibit breast cancer progression ([@bib2]; [@bib16]; [@bib45]; [@bib43]). The fact that RBM47 was able to increase DKK1 secretion therefore suggested that RBM47 may also inhibit Wnt signaling and consequently reduce the tumorigenic fitness of metastatic breast cancer cells. We first tested the effects of RBM47 on cancer cell Wnt responsiveness by treating WT6 cells with recombinant Wnt3A and subsequently measuring the expression of *AXIN2*, a common TCF/β-catenin target gene and a general marker of Wnt activity ([@bib42]; [@bib14]). Doxycycline-induced expression of RBM47 in WT6 cells led to a dampened Wnt3A-dependent *AXIN2* induction ([Figure 8A](#fig8){ref-type="fig"}). This inhibition of *AXIN2* expression was at least partially dependent on DKK1 ([Figure 8B](#fig8){ref-type="fig"}). In agreement with these results, human breast cancers with low RBM47 expression had in general higher levels of Wnt transcriptomic activity when compared to tumors with high RBM47 expression in the TCGA cohort ([Figure 8C](#fig8){ref-type="fig"}).10.7554/eLife.02734.017Figure 8.RBM47 suppresses tumor progression via Wnt inhibition.(**A**) *AXIN2* mRNA levels determined by quantitative real-time RT-PCR in WT6 cells treated with recombinant WNT3A in the presence of increasing concentrations of doxycycline. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**B**) Normalized level of *AXIN2* mRNA inhibition as determined by quantitative real-time RT-PCR in WT6 cells transduced wither with control vector or shRNAmiR constructs targeting the first exon of *DKK1*. The cells were treated with recombinant WNT3A in the presence of increasing concentrations of doxycycline. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**C**) Wnt pathway activity assessed in the TCGA cohort of primary breast tumors, grouped by *RBM47* expression tertiles (L, low; M, medium; H, high). Wnt signature value calculated as sum of z-scores for a curated set of 16 Wnt target genes in breast cancer. p-value determined by linear regression analysis. (**D**) Mammary tumor re-initiation assay. 5,000 WT6 cells implanted orthotopically in mice. RBM47 induced by doxycycline feed. Tumor growth detected by bioluminescence. p-value determined by the log-rank test. N = 20 tumors for each group. (**E**) Quantification of mammary tumor burden by in vivo bioluminescence imaging on day 33 of the experiment shown in (**D**). Data normalized to day 0 for each tumor. p-value calculated by the Wilcoxon rank-sum test. (**F**) Quantification of mammary tumor burden by in vivo bioluminescence imaging in mice inoculated with 231-Brm2 cells transduced with either control (pGIPZ) or DKK1-targeting shRNAmiR constructs. Data normalized to day 0 for each tumor. p-value calculated by one-tailed Wilcoxon rank-sum test. (**G**) Quantification of *ex vivo* brain bioluminescence shown for mice inoculated intracardiacly with WT6 cells transduced with either control (pGIPZ) or DKK1-targeting shRNAmiR constructs in the presence of RBM47, that is doxycycline in diet. One out of 9 (11%) control mice developed robust brain metastasis whereas 8/17 (47%) mice in the DKK1 knockdown groups showed metastasis. p-value calculated by one-tailed Student\'s *t* test. (**H**) Representative images of coronal brain sections analyzed for GFP immunofluorescence from the experiment shown in panel (**G**). Lesion contours are marked in white. Arrowheads indicate the lesions shown in higher magnification on the right; a similar brain area is shown for the control group. Scale bar 500 μm. (**I**) At the global level, RBM47 binds to ∼2500 target mRNAs. However, the abundance or alternative splicing of only a fraction of these change depending on RBM47 status. The target genes represent molecules from various signaling pathways. The net effect of growth promoting and inhibiting alterations determine whether RBM47 loss is beneficial for a particular cancer clone. (**J**) At the target mRNA level, the effects of RBM47 are dependent on the presence of other factors that modulate mRNA processing. Hence, the phenotype of RBM47 loss depends on the intracellular molecular milieu on a per transcript basis. This is exemplified by the interaction of RBM47 with *DKK1* mRNA.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.017](10.7554/eLife.02734.017)10.7554/eLife.02734.018Figure 8---figure supplement 1.DKK1 as a mediator of RBM47-dependent tumor suppression.(**A**) Quantification of mammary tumor burden by in vivo bioluminescence imaging on day 36 after 5,000 WT10 cells were implanted orthotopically in mice. RBM47 induced by doxycycline feed. Data normalized to day 0 for each tumor. p-value calculated by the Wilcoxon rank-sum test. (**B**) *DKK1* mRNA measured by quantitative real-time RT-PCR in 231-BrM2 cells transduced with either control (pGIPZ) or DKK1-targeting shRNAmiR constructs. Error bars represent 95% confidence intervals obtained from multiple PCR reactions. (**C**) Secreted DKK1 protein levels determined by ELISA in WT6 cells transduced with either control (pGIPZ) or DKK1-targeting shRNAmiR constructs, with or without doxycycline treatment.**DOI:** [http://dx.doi.org/10.7554/eLife.02734.018](10.7554/eLife.02734.018)

We then tested the possibility that RBM47 would suppress tumorigenesis by implanting low numbers of WT6 cells at the orthotopic site. The induction of RBM47 by doxycycline was able to significantly delay the emergence of mammary tumors ([Figure 8D](#fig8){ref-type="fig"}), and the tumors that formed were smaller in size ([Figure 8E](#fig8){ref-type="fig"}). This observation was confirmed in WT10 cells ([Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}). In line with this, inhibition of DKK1 expression in the MDA231-BrM2 cells promoted tumor formation in the orthotopic site ([Figure 8F](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}). Finally, we used the two exon 1 DKK1 shRNAmiR constructs ([Figure 7C](#fig7){ref-type="fig"}) to reduce DKK1 levels in the WT6 cells ([Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"}) and tested how this affected the brain metastatic ability of these cells in the presence of RBM47. Only 1/9 mice (16%) injected with control cells developed brain metastasis, whereas 8/17 mice (47%) inoculated with DKK1 RNAi construct transduced cells developed metastasis ([Figure 8G,H](#fig8){ref-type="fig"}). Taken together, these observations suggested that RBM47-dependent suppression of tumor progression was partially mediated by its ability to increase the production of the Wnt antagonist DKK1, a secreted protein that can inhibit tumor phenotypes in metastatic cancer cells.

Discussion {#s3}
==========

Cancer genomes contain numerous genes with low-frequency mutations of unknown functional significance. We have studied one such gene, the previously uncharacterized *RBM47*, and demonstrate that it has tumor suppressive functions in breast cancer. RBM47 acts as a multifunctional RBP modulating alternative splicing and the abundance of several mRNAs, which can lead to inhibition of cancer progression ([Figure 8I,J](#fig8){ref-type="fig"}). These results highlight the significance of infrequent mutations in cancer, the importance of integrated experimental approaches to identify such functionally relevant mutations, and the role of broadly targeted mRNA chaperones as determinants of cancer progression.

RBM47 contains three classical RNA recognition motifs (RRM domains). The closest homologs of RBM47 are Apobec1 complementation factor (A1CF) and hnRNP-Q, which regulate RNA editing ([@bib44]) and splicing and transcript stability, respectively ([@bib12]; [@bib72]). In general, RBPs bind to and influence the function and fate of both pre-mRNAs and mRNAs ([@bib24]). They can operate in large multiprotein complexes that dynamically regulate all the steps of mRNA biogenesis, nuclear export, stability and translation. Individual subunits of these complexes can therefore have diverse phenotypic roles depending on the exact protein complex they are in [@bib11]. Our observations on RBM47 are in line with these known general principles of RBP function.

Our data demonstrate widespread and reproducible RBM47 binding to target mRNAs predominantly in introns and 3′UTRs, with the most robust binding occurring in 3′UTRs. Recent RNA-compete studies have proposed a binding motif for RBM47 in vitro ([@bib54]). Our in vivo HITS-CLIP data does not suggest a clear nucleotide binding specificity for exogenous Flag-tagged RBM47, although some preference was observed for polyU stretches around CIMS sites. It has been shown that the presence of a canonical motif is neither necessary nor sufficient to predict HITS-CLIP binding sites of FUS in both mouse and human brain ([@bib34]), while specific sites suggested by in vitro RNA selection experiments are not enriched in HITS-CLIP derived FMRP binding sites in vivo ([@bib17]). This would suggest that other factors such as RNA accessibility, secondary structure or protein--protein interactions may modulate RBM47 target choice ([@bib37]). Further work is therefore needed for a comprehensive understanding of the determinants of RBM47-mRNA interactions.

We find that RBM47 binds robustly to ∼2500 gene transcripts in human breast cancer cells, with only a subset showing steady state level change or alternative splicing upon RBM47 reintroduction. Given the stringent criteria used to define RBM47-bound and regulated targets and the generally low level of intronic RNA in a cell, it is likely that this subset is an underestimation of the number of RBM47-regulated transcripts, and does not take into account the potential for regulatory events, such as re-localization, that may not alter steady state transcript levels. The complex interplay of RBPs in agonistic and antagonistic modulation of mRNA is becoming increasingly apparent. For example, the RRM-domain containing protein HuR modulates the destabilizing effects of miRNAs ([@bib6]; [@bib33]; [@bib74]) and AUF1 ([@bib79]) on common target transcripts. The data presented here suggest that target-specific RBM47 regulation may arise through modulation of accessibility of other factors to a common mRNA transcript.

RBM47 binds and regulates transcripts that encode for proteins of several different biological functions. The effects of reduced RBM47 activity on cancer cell fitness, determined by the sum phenotypic output of all regulated target transcripts, may therefore vary depending on the context. Such pleiotropic effects could target multiple steps of cancer progression. Indeed, even though RBM47 loss was associated with metastatic cancer clones in our model systems, evidence for selection against RBM47 was detected already in primary breast cancers. One of the most highly bound RBM47 mRNA targets, the secreted Wnt inhibitor *DKK1*, is stabilized by RBM47 and partially mediates RBM47 tumor suppressive function. Interestingly, *rbm47* knockdown in zebra fish embryos leads to a headless phenotype mediated via up-regulation of the *wnt8a* pathway ([@bib27]). In addition to DKK1, our analysis identified a number of potential mediators of RBM47 effects for future studies.

From a general perspective, the present findings illuminate two concepts. First, we show that low-frequency cancer mutations can give rise to tumorigenic phenotypes. Our work highlights the power of orthogonal approaches for the analysis of cancer genome resequencing data. Second, we show that loss of a broadly targeted and multifunctional RBP can increase the fitness of certain cancer cell clones in support of metastasis. This complements previous findings of RNA-binding proteins as mediators of oncogenic phenotypes ([@bib32]; [@bib55]; [@bib63]; [@bib19]; [@bib71]). Deregulation of RNA-binding proteins is thus emerging as a prominent source of complex transcriptomic diversity that can serve as a platform for the selection of metastatic traits during tumor progression.

Materials and methods {#s4}
=====================

Cell lines {#s4-1}
----------

The metastatic breast cancer cell lines have been previously described ([@bib31]; [@bib46]; [@bib7]). SKBR3, ZR-75-30 and HCC1954 cells were obtained from ATCC (Manassas, VA). For retrovirus and lentivirus production, GPG29 and 293T cells, respectively, were utilized. All cell lines were maintained under standard tissue culture conditions. Single cell-derived clones were isolated utilizing fluorescence-activated cell sorting from genetically engineered 231-BrM2 (WT10, MUT3) and CN34-BrM2 (WT6) cells.

cDNA expression and RNAi {#s4-2}
------------------------

For RBM47 restoration, *RBM47* was cloned into the pBABE-puro retroviral expression vector. The *RBM47*^*I281fs*^ was generated by site-directed mutagenesis. Virus was generated in the GPG29 packaging cells. For the generation of doxycycline-inducible expression constructs, both wild type and mutant FLAG-RBM47 were cloned into the pRetroX-Tight-Pur expression system (Clontech, Mountain View, CA).

For RNAi-mediated gene silencing, RBM47 pGIPZ shRNA constructs (clones V2LHS_176331 and V3LHS_393928, respectively) were obtained from Open Biosystems (Lafayette, CO). The DKK1 shRNAmiR constructs were designed based on the rules described by [@bib25] and cloned into the pGIPZ vector as described ([@bib23]) using the following oligonucleotide templates:DKK1miRm: TGCTGTTGACAGTGAGCGACGGGTCTTTGTCGCGATGGTATAGTGAAGCCACAGATGTATACCATCGCGACAAAGACCCGGTGCCTACTGCCTCGGADKK1miRn: TGCTGTTGACAGTGAGCGACACCTTGAACTCGGTTCTCAATAGTGAAGCCACAGATGTATTGAGAACCGAGTTCAAGGTGGTGCCTACTGCCTCGGADKK1miRo: TGCTGTTGACAGTGAGCGCCAACTCAATCCTAAGGATATATAGTGAAGCCACAGATGTATATATCCTTAGGATTGAGTTGATGCCTACTGCCTCGGADKK1miRp: TGCTGTTGACAGTGAGCGACAGTAAATTACTGTATTGTAATAGTGAAGCCACAGATGTATTACAATACAGTAATTTACTGCTGCCTACTGCCTCGGADKK1miRq: TGCTGTTGACAGTGAGCGAAACGGAAGTGTGATATGTTTATAGTGAAGCCACAGATGTATAAACATATCACACTTCCGTTCTGCCTACTGCCTCGGA

The pGIPZ empty vector was used as a control.

Animal studies {#s4-3}
--------------

All animal experiments were performed in accordance with a protocol approved by MSKCC Institutional Animal Care and Use Committee. Lung metastasis assays were conducted in 5--7 week old female NOD/SCID mice. Brain metastasis and mammary tumor assays were carried out using 5--7 week old female athymic nude mice. In vivo bioluminescence imaging was performed using the IVIS Spectrum Xenogen machine (Caliper Life Sciences, Hopkinton, MA). For orthotopic mammary tumor assays, cells were mixed with Matrigel. Injections were confirmed and tumor growth was followed by bioluminescent imaging. Statistical significance of tumor and metastasis free survival was assessed by the log-rank test. Differences in raw and normalized bioluminescence signal was assessed by the Student\'s *t* test and Wilcoxon rank-sum test, respectively. Brain images were acquired with a Leica SP5 up-right confocal microscope and Zeiss AxioVert 200 M using 20X and 5X objectives. Image analysis was performed with Metamorph and ImageJ softwares.

mRNA and protein detection {#s4-4}
--------------------------

Total RNA was extracted using PrepEase RNA spin kit (USB, Cleveland, OH). We used Transcriptor First Strand cDNA Synthesis Kit (Roche, Indianapolis, IN) for cDNA synthesis. Quantitative PCR was performed using predesigned Taqman gene expression assays (Life Technologies, Carlsbad, CA) and the 7900HT or ViiA 7 real-time PCR systems (Applied Biosystems/Life Technologies). *TBP* was used as a housekeeping control gene. mRNA stability was assessed by performing quantitative PCR after actinomycin D treatment. For immunoblotting, antibodies recognizing RBM47 (HPA006347; Sigma, St. Luis, MO), α-tubulin (11H10; Cell Signaling, Danvers, MA) and ACTB (Sigma) were utilized. Secondary antibodies were HRP (Pierce, Rockford, IL) or fluorescence (LiCor, Lincoln, NE) conjugated. Immunostaining for RBM47 (HPA006347; Sigma) was performed according to standard protocols in the MSKCC Molecular Cytology Core Facility on paraffin embedded tissue blocks. Secreted protein was detected by ELISA (R&D, Minneapolis, MN).

HITS-CLIP {#s4-5}
---------

231BrM2 tet-on FLAG-RBM47 cells were treated with 1 ng/ml doxycycline for 3 days before 254 nm UV crosslinking at 400 mJ/cm^2^ on a bed of ice (Stratalinker2400; Stratagene, La Jolla, CA). Samples were processed for HITS-CLIP as previously described ([@bib39]) using an anti-Flag antibody (F3165; Sigma), and omitting 3′ linker ligation in favor of direct labeling of protein-bound RNA with ^32^P-γ-ATP. Non-crosslinked cells were used as a negative control, with IPed Flag-RBM47 protein detected using a second anti-Flag antibody (F7425; Sigma). Purified RBM47-bound RNA fragments were polyA tailed (E-PAP; NEB), and reverse transcribed (Superscript III; Invitrogen, Carlsbad, CA) in the presence of Br-dUTP (Sigma). Unique polydT-NV RT-primers were used per replicate, containing Solexa sequences separated by an abasic furan (that serves as an ApeI cut site), a 6 nt degenerate region and a 6 nt index sequence to allow for multiplexing during sequencing.RT Primer 1pGCACTGTTN~6~GATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAGACGGCATACGAT~20~VNRT Primer 2pGCGAAACTN~6~GATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAGACGGCATACGAT~20~VN

BrdU-cDNA was stringently purified by IP (sc-32323; Santa Cruz, Dallas, TX) using ProteinG dynabeads (Invitrogen), eluted from the beads via BrdU competitive elution (Sigma), and re-immunoprecipitated. cDNA was circularized on bead (CircLigase ssDNA Ligase II, Epicentre, Madison, WI), washed and digested with ApeI (NEB, Ipswich, MA) to relinearize. cDNAs were eluted from the beads by heating to 98C in Phusion HF Buffer (NEB), then PCR amplified using Phusion DNA polymerase (NEB) and SYBR Green I (Invitrogen) in an iQ5 real-time PCR machine in order to monitor amplification, with the samples being removed when the RFU signal reached ∼1000.

P5---aatgatacggcgaccaccgacaggttcagagttctacagtccgacg

P3---caagcagaagacggcata

PCR products were purified using MinElute columns (Qiagen, Valencia, CA) as per manufacturer\'s instructions and quantified using Quant-It (Invitrogen). cDNA was multiplexed and sequenced using Illumina Hi-Seq (small RNA sequencing primer---cgacaggttcagagttctacagtccgacgatc). All data analysis was done using the Galaxy platform ([@bib28]), as previously described ([@bib39]; [@bib13]; [@bib17]; [@bib75]).

RT-PCR validation {#s4-6}
-----------------

RT-PCR validiation was carried out using total RNA from MDA231-BrM2 (Control) and WT10 cells (iScript, Bio-Rad, Accuprime Pfx Supermix 1, Life Technologies) as previously described ([@bib40]). In all cases lanes 1--3 contain an equal mixture of control and WT10 cell cDNA amplified at *n-1*, *n* and *n+1* cycles, lane 4 contains an absence of reverse transcriptase control (−RT), with all other lanes corresponding to replicate samples of the indicated cell type amplified to *n* cycles. IR and ΔI calculated using ImageJ ([@bib57]).

Bioinformatic analysis {#s4-7}
----------------------

All analyses were conducted using R. Microarray data from human untreated tumor data sets (GSE2603 \[[@bib46]\] and GSE2034 \[[@bib70]\]) were preprocessed as described ([@bib76]). For the RNA-seq TCGA data set, normalized mRNA z-scores were downloaded from the TCGA cBio portal ([@bib9]). The microarray data from metastatic cell lines ([@bib46]; [@bib7]) were processed with GCRMA together with updated probe set definitions using R packages *affy*, *gcrma* and *hs133ahsentrezgcdf* (version 10). Unsupervised hierarchical clustering was performed using the function *heatmap.2* with Pearson\'s correlation coefficient as the similarity metric. For survival analysis, a Cox proportional hazards model was utilized as implemented in the *coxph* function in the R-package *survival*. For RNA-seq analysis of the cell lines, raw paired-end sequencing data were mapped to human genome (hg19 build) with STAR2.3.0 ([@bib22]) using standard options. Reads mapped to each transcript were counted by HTSeq v0.5.4 ([@bib1]) with default settings. The read count table was normalized to library size by DESeq ([@bib1]). Correlation with RBM47 expression was assessed by Pearson\'s correlation coefficient utilizing the R functions *cor* and *cor.test*. Wnt pathway activity in clinical tumors was assessed utilizing a curated list of Wnt target genes in breast cancer ([@bib43]) and calculating sums of z-scores for each tumor.

Accession numbers {#s4-8}
-----------------

RNA-seq and HITS-CLIP data have been deposited to the Gene Expression Omnibus under the accession numbers GSE53779 and GSE58381.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer" for consideration at *eLife*. Your article has been favorably evaluated by Tony Hunter (Senior editor) and 2 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The reviewers felt that the identification of the RBM47 RNA-binding protein as a regulator of metastasis was an important contribution that could be published in *eLife*. However, the following issues would need to be addressed before we can consider the work further for publication in *eLife*.

Major comments:

1\) A critical issue is whether RBM47 has a specific role in regulating metastasis as opposed to more broadly affecting cell proliferation and growth. More specifically, [Figures 2 and 3](#fig2 fig3){ref-type="fig"} attempt to show that RBM47 suppresses experimental metastases in the brain and the lung. However, without examining whether RBM47 overexpression and knockdown also affect cell proliferation in culture and primary tumor growth in mice, it is unclear whether RMB47 specifically regulates metastasis vs. cell proliferation. Indeed, [Figure 8C-8E](#fig8){ref-type="fig"} shows that expression of RBM47 drastically inhibits primary tumor growth, suggesting a possible role of RBM47 in regulating primary tumor growth, with a possible downstream effect on metastasis. [Figure 8](#fig8){ref-type="fig"} aims to demonstrate a critical role of DKK1 downstream of RBM47 in suppressing tumor progression. Since [Figure 8F](#fig8){ref-type="fig"} shows that DKK1 knockdown resulted in significantly bigger primary tumors, it is again unclear whether there is any specific effect on metastasis. For this work to be of sufficient impact for publication in *eLife* experiments to demonstrate a specific role of RBM47 in metastasis, as opposed to general cell proliferation, are required.

2\) Given the pleiotropic effects of the RBM47 protein on cellular RNA metabolism, it is possible that multiple target RNAs are involved and stronger evidence that the DKK1 and Wnt signaling pathways are the primary targets would be required. Possible experiments include:

a\) Examining whether RBM47 expression is inversely correlated with Wnt gene signatures in the human breast tumor datasets described in [Figure 1](#fig1){ref-type="fig"}.

b\) Examining if weaker DKK1 shRNAs have the appropriate effect on tumor growth and metastasis as related to RBM47. This is based on the observation that [Figure 8S1B](#fig8s1){ref-type="fig"} shows that RBM47 overexpression resulted in ∼3-fold increase of DKK1 protein level. However, DKK1 shRNAs used in suppression of DKK1 protein to an almost undetectable level; much lower than the level in the control cells without RBM47. Therefore, the observed tumor growth and brain metastasis formation upon DKK1 knockdown ([Figure 8F-8H](#fig8){ref-type="fig"}) may not be necessarily related to RBM47. To test this, much weaker DKK1 shRNAs should be used to bring down the DKK1 protein level to the level in the control cells as shown in [Figure 8S1B](#fig8){ref-type="fig"} to test its effect on tumor growth and metastasis. Ideally, depletion of the relevant Wnts expressed by these cells would establish the importance of DKK1 as a target for metastasis suppression by RBM47.

3\) Most of the experiments were carried out with the metastatic variants of the MDA-MB-231 cell line, and one would like to know how general the effect of manipulating RBM47 levels on breast cancer cell metastasis is. Some experiments were carried out with CN34 cells, a metastatic breast cancer line derived from a pleural effusion at MSKCC, and these data support the conclusion that RBM47 acts to reduce metastasis. In this regard, the authors showed that CN34-BrM2 cells have low levels of RBM47 -- did they check if RBM47 expression reduces the level of brain metastases? Have any other breast cancer cell lines been assessed for the effects of RBM47 expression or depletion on metastatic potential (e.g. lines like SKBR3 that have high endogenous RBM47)?

Minor comments:

4\) It would improve the CLIP data to normalize their number of tags to the abundance of that RNA from the RNA-seq data. This might reveal a more relevant binding to intron sequences (which are generally present at low levels).

5\) It is possible that effects on alternative splicing can influence RNA stability due to sequence differences in mature mRNAs. Although not required for publication, it would improve the manuscript if the authors determined whether there is a significant overlap between mRNAs with altered splicing and abundance in order to see if these two sets are related.

6\) The CLIP experiment was done with over-expressed RBM47 protein and this has the potential to influence the observed binding sites. This caveat should at least be made explicit in the manuscript.

7\) The key functional data presented in this study ([Figures 2, 3, and 8](#fig2 fig3 fig8){ref-type="fig"}) relied on overexpressing RBM47 in tumor cells. It is unclear how the level of RBM47 overexpression is compared to the physiological level of RBM47 in normal cells or the parental non-metastatic cells. This information is critical to determine whether the observed tumor growth reduction upon RBM47 overexpression is due to physiological effect of RBM47 or due to toxic effects of overexpressed RBM47.

8\) It would significantly strengthen the manuscript if the effect of RBM47 on metastasis could be ascribed to a specific step in metastasis (e.g. invasion, survival, stem cell properties, interaction with stromal cells, or per-metastatic niche).

9\) Since no biochemical analysis was performed on the RBM47 I281fs mutant, it is unclear whether this mutation completely abolishes RBM47 function. Therefore, in [Figure 2](#fig2){ref-type="fig"}, LM2 cells expressing a vector control should also have been used to compare the effect on expressing WT and MUT RBM47.

10\) In [Figure 2F](#fig2){ref-type="fig"} shRNAs were used to knock down RBM47 in LM2 cells to determine the effects on lung colonization. Western blotting analysis should be presented to show the RBM47 knockdown levels. Instead, it is confusing why [Figure 3S1A](#fig3){ref-type="fig"} shows the western blot with CN34 cells.

11\) [Figure 3A-3D](#fig3){ref-type="fig"} should include staining for RBM47 in the parental cells or cells expressing a control vector. Otherwise, it is unclear what is the negative RBM47 staining. [Figure 3S1B](#fig3){ref-type="fig"} states these are RBM47 negative tumors, although many show positive signals. It is important to co-stain for a marker specific for tumor cells, so that expression of RBM47 in tumor cells vs. stromal cells can be separated.

10.7554/eLife.02734.023

Author response

We would like to thank the reviewers for their time and insightful comments. We were happy to see that all of you found our work interesting and that the general assessment was positive. The comments highlighted important points, all of which we have now addressed. We feel that this has improved our paper. We have also decided to eliminate the term hnRNP from the paper, as it is an outdated concept, originally meant to refer to abundant nuclear RNA binding proteins that coat hnRNA. However, the term essentially has no current meaning except for historical purposes.

*1) A critical issue is whether RBM47 has a specific role in regulating metastasis as opposed to more broadly affecting cell proliferation and growth. More specifically,* [*Figures 2 and 3*](#fig2 fig3){ref-type="fig"} *attempt to show that RBM47 suppresses experimental metastases in the brain and the lung. However, without examining whether RBM47 overexpression and knockdown also affect cell proliferation in culture and primary tumor growth in mice, it is unclear whether RMB47 specifically regulates metastasis vs. cell proliferation. Indeed,* [*Figure 8C-8E*](#fig8){ref-type="fig"} *shows that expression of RBM47 drastically inhibits primary tumor growth, suggesting a possible role of RBM47 in regulating primary tumor growth, with a possible downstream effect on metastasis.* [*Figure 8*](#fig8){ref-type="fig"} *aims to demonstrate a critical role of DKK1 downstream of RBM47 in suppressing tumor progression. Since* [*Figure 8F*](#fig8){ref-type="fig"} *shows that DKK1 knockdown resulted in significantly bigger primary tumors, it is again unclear whether there is any specific effect on metastasis. For this work to be of sufficient impact for publication in eLife experiments to demonstrate a specific role of RBM47 in metastasis, as opposed to general cell proliferation, are required*.

We agree with the assessment that the data presented in the manuscript does not show specific effects of RBM47 as a suppressor of metastatic progression. In fact, the data in [Figure 8](#fig8){ref-type="fig"} clearly show effects on mammary tumor formation as well. This is in line with the data from clinical patient cohorts: RBM47 mutations have been identified in primary breast cancers. Thus, we do not believe that RBM47 inactivation would result in a specific pro-metastatic phenotype. However, as described if [Figure 1A](#fig1){ref-type="fig"} and associated text, we did identify RBM47 through an analysis of metastatic breast cancer model systems and clinical datasets. This showed that RBM47 expression is reduced in highly metastatic subpopulations of breast cancer cells when compared to their weakly metastatic but highly tumorigenic parental lines, and that low *RBM47* expression correlates with poor patient outcome. Moreover, in the breast cancer brain metastasis sequenced by Ding et al. (2010), the RBM47 mutation was highly enriched when compared to the primary tumor. Combined with our functional data, all this evidence suggests that the most aggressive cancer cell populations that are most likely to form metastases benefit from RBM47 loss and hence RBM47 loss is further selected for during metastatic progression.

We would like to address here the widespread idea that 'true' metastasis genes and functions are not involved at all in primary tumor formation. In fact, with the exception of genes that mediate the last stage of the metastatic process -- overt colonization of specific organ microenvironments -- the majority of genes implicated in metastasis confer advantages to cancer cells already in a primary tumor. Otherwise, clones overexpressing such pro-metastatic genes would not become selected and enriched enough in primary tumors for their expressed genes to score as predictive metastasis markers or signatures. These genes are not tumor initiation or early progression oncogenes. Their functions provide a selective advantage to invasive cancer cells that venture into hostile microenvironments, for example, at the invasive front. The clones expressing these genes are thereby primed for metastatic seeding in distant sites, where their advantageous traits may undergo additional selection and amplification. Extensive clinical and experimental evidence for this concept has been presented in our work (1-5) and the work of others. Therefore, the idea that authentic pro-metastatic genes contribute to tumorigenesis only in distant organs and not at all in primary tumors is incorrect, in our view. We have succinctly annotated the revised manuscript in order to clarify this issue.

The evolutionary process that shapes tumor progression at the primary site pre-selects phenotypes that will later on enhance the metastatic fitness of the disseminated cells. As the vast majority of disseminated cancer cells die, this pre-selection is essential for cancer cell survival at the early stages of metastasis initiation. For this reason, the majority of important mediators of metastasis identified to date also have detectable effects on tumor growth at the primary site. This is the case with RBM47 as well.

The most important finding of our paper is the demonstration that loss of RBM47, a previously uncharacterized RNA chaperone with widespread binding across the transcriptome, is selected for during metastatic cancer progression. We show that this is partially mediated by enhanced activation the Wnt signaling pathway, but we believe that other pro-tumorigenic signaling pathways could also be involved in the process. Our intention therefore is not to suggest that RBM47 has specific functions suppressing metastasis, but rather that its loss contributes to the establishment of the most aggressive cancer phenotypes that are vital to metastatic dissemination. This is an important concept that highlights the importance of alterations in transcriptomic homeostasis as a source of phenotypic diversity required for cancer progression. In order to clarify this, we have reworded the Abstract and manuscript.

*2) Given the pleiotropic effects of the RBM47 protein on cellular RNA metabolism*, *it is possible that multiple target RNAs are involved and stronger evidence that the DKK1 and Wnt signaling pathways are the primary targets would be required. Possible experiments include:*

*a) Examining whether RBM47 expression is inversely correlated with Wnt gene signatures in the human breast tumor datasets described in* [*Figure 1*](#fig1){ref-type="fig"}.

*b) Examining if weaker DKK1 shRNAs have the appropriate effect on tumor growth and metastasis as related to RBM47. This is based on the observation that* [*Figure 8S1B*](#fig8){ref-type="fig"} *shows that RBM47 overexpression resulted in ∼3-fold increase of DKK1 protein level. However, DKK1 shRNAs used in suppression of DKK1 protein to an almost undetectable level; much lower than the level in the control cells without RBM47. Therefore, the observed tumor growth and brain metastasis formation upon DKK1 knockdown (*[*Figure 8F-8H*](#fig8){ref-type="fig"}*) may not be necessarily related to RBM47. To test this, much weaker DKK1 shRNAs should be used to bring down the DKK1 protein level to the level in the control cells as shown in* [*Figure 8S1B*](#fig8){ref-type="fig"} *to test its effect on tumor growth and metastasis. Ideally, depletion of the relevant Wnts expressed by these cells would establish the importance of DKK1 as a target for metastasis suppression by RBM47*.

Our work indicates that RBM47 has multiple target molecules. This is in line with the known principles of nuclear RNA binding protein function; they act as part of large protein complexes to facilitate multiple aspects of mRNA biogenesis. Indeed, we provide evidence that RBM47 regulates both mRNA stability and splicing. As the various target mRNAs of RBM47 encode for proteins that function in several biological processes, the phenotypic output of RBM47 loss will therefore have pleiotropic effects. Our data in [Figure 7](#fig7){ref-type="fig"} show the importance of other mRNA processing factors as regulators of RBM47 phenotypic output underscoring the fact that loss of RBM47 can have context-dependent effects. Even with the widespread binding pattern of RBM47, we demonstrate here that cells with reduced RBM47 function are repeatedly selected for during tumor progression. Thus, at least in some circumstances, the net effect of RBM47 loss is beneficial for a cancer cell.

In the current study, we focused on DKK1 as one of the downstream mediators of RBM47 action. DKK1 was chosen for two reasons: (i) it was one of the most prominent target transcripts of RBM47 as determined by HITS-CLIP and (ii) it is a known modulator of the Wnt pathway. We show that RBM47 can indeed inhibit Wnt signaling by stabilizing DKK1. We also demonstrate that DKK1 knockdown is able to partially rescue the tumor suppressive effects of RBM47. These results suggest, as pointed out by the referees, that RBM47 expression should correlate negatively with a Wnt responsive signature in clinical data sets. In agreement with the prediction, we have now found that tumors with low RBM47 expression tend to have higher expression of Wnt target genes, as determined by pathway analysis using a curated breast cancer Wnt signature (6). Following the option 2(a) suggested by the referees, these new data have been added into the new [Figure 8C](#fig8){ref-type="fig"} and associated text as requested.

Despite providing evidence of DKK1 as a mediator of the pro-tumorigenic effects of RBM47 loss, we do not mean to suggest that DKK1 is the only important target transcript of RBM47. DKK1 is but one of many RBM47 targets, the balance of which makes a *net* positive contribution to metastasis, much in the same way that dysfunctions in other epigenetic regulators do. In this paper we use DKK1 as an important example, but acknowledge the possible contributions of other RMB47 targets.

The upshot of our work is that the loss of a promiscuous RNA-binding protein can, despite its large number of functionally unrelated target mRNAs, lead to the emergence of pro-metastatic cancer cell traits. This finding complements the recent findings of mutations in epigenetic regulators in cancer, and highlights the importance of widespread perturbations in RNA homeostasis as a source of cancer cell phenotypes. In order to clarify this point, the revised manuscript highlights other potential mediators of RBM47 effects for further study..

*3) Most of the experiments were carried out with the metastatic variants of the MDA-MB-231 cell line, and one would like to know how general the effect of manipulating RBM47 levels on breast cancer cell metastasis is. Some experiments were carried out with CN34 cells, a metastatic breast cancer line derived from a pleural effusion at MSKCC, and these data support the conclusion that RBM47 acts to reduce metastasis. In this regard, the authors showed that CN34-BrM2 cells have low levels of RBM47* -- *did they check if RBM47 expression reduces the level of brain metastases? Have any other breast cancer cell lines been assessed for the effects of RBM47 expression or depletion on metastatic potential (e.g*. *lines like SKBR3 that have high endogenous RBM47)?*

We identified RBM47 as a suppressor of breast cancer progression through an integrative approach that combined gene expression information from metastatic breast cancer models with mutational and gene expression data from clinical datasets. Importantly, the clinical cohorts utilized in this study comprise hundreds of tumor samples, providing critical evidence that the observations made in our experimental model systems have more general clinical relevance. To this end, the new analysis in [Figure 8C](#fig8){ref-type="fig"} further strengthens our conclusions by providing additional evidence of the negative correlation between RBM47 expression and Wnt pathway activity.

We agree that increasing the number of model systems increases confidence in the general relevance biological data. Our study therefore contains experimental results from several cell line models (MDA231, CN34, SKBR3 and ZR-75-30) as well as clonal metastatic derivatives, including one derived from the CN34-BrM2 cells (WT6). The results on the effects of RBM47 on the brain metastatic potential of these cells is shown in [Figure 3G](#fig3){ref-type="fig"}. The cell lines from which the three single cell-derived brain metastatic clones used in this study were isolated has been clarified in the Methods section of the revised manuscript. In sum, we feel that the combined power of large clinical data sets and several experimental models give sufficient confidence in the generality of our findings.

Minor comments:

*4) It would improve the CLIP data to normalize their number of tags to the abundance of that RNA from the RNA-seq data. This might reveal a more relevant binding to intron sequences (which are generally present at low levels)*.

We agree that normalizing HITS-CLIP data to total RNA reads could reveal more prominent intronic binding patterns. However, our existing RNAseq data corresponding to the HITS-CLIP experiments shown in [Figures 4 and 5](#fig4 fig5){ref-type="fig"} are polyA-selected and therefore, given the low level of reads mapping to introns, it is not suitable for intronic HITS-CLIP normalization. In order to take the low level of intronic RNA into account, and anticipating that pre-mRNA may be present at levels approximately 1000x lower than mRNA (7), we have lowered the threshold for determining robust RBM47 binding in introns while maintaining a conservative cut-off of total HITS-CLIP reads in clusters in the vicinity of alternatively spliced exons (see [Figure 4D](#fig4){ref-type="fig"}). While this approach increases the sensitivity for detecting intronic binding, we do agree that our data may underestimate the degree to which RBM47 intronic binding is associated with RBM47-dependent alternative splicing. To clarify this, we have amended the text in the revised manuscript.

*5) It is possible that effects on alternative splicing can influence RNA stability due to sequence differences in mature mRNAs. Although not required for publication, it would improve the manuscript if the authors determined whether there is a significant overlap between mRNAs with altered splicing and abundance in order to see if these two sets are related*.

Alternative splicing can alter mRNA stability, e.g. through the introduction of cryptic NMD exons (8). However, at the cutoff levels used in this study, we did not see any overlap between the transcripts that underwent alternative splicing and genes that showed altered message levels upon RBM47 reintroduction. As discussed in Response 4, deeper intronic RNA sequencing could identify additional RBM47-dependent splicing events, which could also reveal links to mRNA stability, but based on current data, alternative splicing does not seem to be a major determinant of altered mRNA stability in the context of RBM47.

*6) The CLIP experiment was done with over-expressed RBM47 protein and this has the potential to influence the observed binding sites. This caveat should at least be made explicit in the manuscript*.

The text has been revised as requested.

*7) The key functional data presented in this study (*[*Figures 2, 3, and 8*](#fig2 fig3 fig8){ref-type="fig"}*) relied on overexpressing RBM47 in tumor cells. It is unclear how the level of RBM47 overexpression is compared to the physiological level of RBM47 in normal cells or the parental non-metastatic cells. This information is critical to determine whether the observed tumor growth reduction upon RBM47 overexpression is due to physiological effect of RBM47 or due to toxic effects of overexpressed RBM47*.

We agree that protein overexpression is a potential source of artifacts. In order to control for this, however, we have taken several measures:

a\) shRNA constructs were used to validate the metastasis suppressive effects of RBM47 in vivo ([Figure 2F-H](#fig2){ref-type="fig"} and [Figure 2--figure supplement 1D-G](#fig2s1){ref-type="fig"}), as well as the capability of RBM47 loss to regulate DKK1 mRNA levels ([Figure 7A](#fig7){ref-type="fig"} and [Figure 7--figure supplement 1A](#fig7s1){ref-type="fig"}).

b\) Single cell-derived metastatic cell lines with doxycycline-inducible RBM47 expression were generated. This allowed us to control RBM47 protein levels, as can be seen in [Figure 3--figure supplement 2D-E](#fig3s2){ref-type="fig"}. The effects on DKK1 expression were detectable already at RBM47 protein levels lower or similar to that seen in control cells expressing only endogenous RBM47 (doxycycline 2.5ng/ul in WT6 cells, [Figure 3--figure supplement 2D](#fig3s2){ref-type="fig"} and [Figure 6H](#fig6){ref-type="fig"}), even though no effect was seen in cell proliferation in vitro, as shown by the new piece of data in [Figure 3--figure supplement 2F](#fig3s2){ref-type="fig"}.

c\) In the RNA-seq analysis, stringent conditions were applied to ensure that the RBM47 responsive signature consisted of genes that were changed already at the lowest detectable level of RBM47 protein expression. This signature was able to classify human cancer specimens in a way that correlated with RBM47 expression, as is shown in [Figures 6D-E](#fig6){ref-type="fig"} and [Figure 6--figure supplement 1C](#fig6s1){ref-type="fig"}.

In addition, DKK1 knockdown was able to partially rescue the effects of RBM47 reintroduction in the brain metastasis assay ([Figure 8G-H](#fig8){ref-type="fig"}). Thus, we feel that the collective evidence, including data from both loss-of-function and gain-of-function genetic experiments as well as bioinformatic analysis of large clinical datasets, support the conclusions of the paper.

*8) It would significantly strengthen the manuscript if the effect of RBM47 on metastasis could be ascribed to a specific step in metastasis (e.g. invasion, survival, stem cell properties, interaction with stromal cells, or per-metastatic niche)*.

As discussed in Response 2, RBM47 like all nuclear RNA binding proteins is likely to function in multiprotein complexes to facilitate mRNA biogenesis. In line with this, we find that RBM47 binds to multiple target mRNAs. These targets do not belong to a distinct pathway or molecular class, but rather, represent transcripts that encode for proteins that have functional roles in several biological processes. We focused on DKK1 as one of the many target molecules of RBM47 and show that RBM47 can modulate Wnt signaling via DKK1 stabilization. The Wnt pathway can modulate multiple breast cancer phenotypes including proliferation (9-11), migration (6) and stem cell fitness (12). In line with this, we show in [Figure 8](#fig8){ref-type="fig"} that RBM47 can both inhibit tumor re-initiation and growth. However, it remains possible that further phenotypic characterization could reveal additional functional consequences of RBM47 loss. Thus, given the pleiotropic nature of RBM47 function, we believe that ascribing the tumor suppressive functions of RBM47 to a single step in the metastatic cascade would be an over-simplification of its biological function.

*9) Since no biochemical analysis was performed on the RBM47 I281fs mutant, it is unclear whether this mutation completely abolishes RBM47 function. Therefore, in* [*Figure 2*](#fig2){ref-type="fig"}*, LM2 cells expressing a vector control should also have been used to compare the effect on expressing WT and MUT RBM47*.

Even though I281fs mutant mRNA was expressed at similar levels than wildtype *RBM47* (see [Figure 2--figure supplement 1A](#fig2s1){ref-type="fig"}), Western blot analyses indicate that the RBM47 I281fs mutant protein is not expressed at doxycycline dosages that induce wildtype RBM47 expression, as can be seen in the data provided in new [Figure 2--figure supplement 1B](#fig2s1){ref-type="fig"}. Furthermore, the experiments shown in [Figure 3H-J](#fig3){ref-type="fig"} demonstrate that doxycycline-induced expression of I281fs does not have any effect on brain metastasis formation by the MUT3 cells. Collectively this suggests that the RBM47 I281fs mutant expressing cells function as a negative control.

*10) In* [*Figure 2F*](#fig2){ref-type="fig"} *shRNAs were used to knock down RBM47 in LM2 cells to determine the effects on lung colonization. Western blotting analysis should be presented to show the RBM47 knockdown levels. Instead, it is confusing why* [*Figure 3S1A*](#fig3){ref-type="fig"} *shows the western blot with CN34 cells*.

As requested, the Western blot related to [Figure 2F](#fig2){ref-type="fig"} has been added to [Figure 2--figure supplement 1D](#fig2s1){ref-type="fig"}. For clarity, the Western blot for CN34 cells has been moved to [Figure 2--figure supplement 1E](#fig2s1){ref-type="fig"}.

*11)* [*Figure 3A-3D*](#fig3){ref-type="fig"} *should include staining for RBM47 in the parental cells or cells expressing a control vector. Otherwise, it is unclear what is the negative RBM47 staining.* [*Figure 3S1B*](#fig3){ref-type="fig"} *states these are RBM47 negative tumors, although many show positive signals. It is important to co-stain for a marker specific for tumor cells, so that expression of RBM47 in tumor cells vs. stromal cells can be separated*.

The I281fs mutation introduces a premature stop codon. For this reason, the epitope against which the RBM47 antibody was developed is missing from the mutant protein. RBM47 mutant expressing cells can therefore be used as a negative control, as is shown in [Figure 3C](#fig3){ref-type="fig"}. We do agree, however, that using the word 'negative' in this context is inappropriate. The text has been revised to more accurately describe the staining as 'weak' or 'low'. As requested, we have also complemented the analysis by including data on a tumor-specific marker. The revised [Figure 3--figure supplement 1A](#fig3s1){ref-type="fig"} and associated text now show examples of metastatic nodules that have either high or low RBM47 expression as determined by immunohistochemistry against RBM47 and human vimentin. We have also assessed tumor cell proliferation in these tumors using an antibody against Ki67. These data show that both the RBM47 high and low nodules proliferate at similar rates, further emphasizing the conclusion that while some metastases do reduce the transgene expression, others are capable of developing in the presence of RBM47.
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